Abbott's TRILIPIX® (fenofibric Acid) In Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia And Type 2 Diabetes Meet Amer
Abbott's TRILIPIX® (fenofibric Acid) In Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia And Type 2 Diabetes Meet Amer
Abbott's (NYSE: ABT) TRILIPIX® (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium achieved individual and combined lipid targets in patients with mixed dyslipidemia and type 2 diabetes. In these patients, the combination of TRILIPIX and rosuvastatin helped up to three times more patients simultaneously reach all three key lipid targets HDL, triglycerides and LDL than the pre-determined monotherapy.